Integrated approach to designing growth factor delivery systems
- PMID: 17644610
- DOI: 10.1096/fj.06-7873com
Integrated approach to designing growth factor delivery systems
Abstract
Growth factors have been widely used in strategies to regenerate and repair diseased tissues, but current therapies that go directly from bench to bedside have had limited clinical success. We hypothesize that engineering successful therapies with recombinant proteins will often require specific quantitative information of the spatiotemporal role of the factors and the development of sophisticated delivery approaches that provide appropriate tissue exposures. This hypothesis was tested in the context of therapeutic angiogenesis. An in vitro model of angiogenesis was adapted to quantify the role of the concentration/gradient of vascular endothelial growth factor [VEGF(165)] on microvascular endothelial cells, and a delivery system was then designed, based on a mathematical model, to provide the desired profile in ischemic mice hindlimbs. This system significantly enhanced blood vessel formation, and perfusion and recovery from severe ischemia. This general approach may be broadly applicable to growth factor therapies.
Similar articles
-
Host immune competence and local ischemia affects the functionality of engineered vasculature.Microcirculation. 2007 Feb;14(2):77-88. doi: 10.1080/10739680601131101. Microcirculation. 2007. PMID: 17365663
-
Sequential delivery of TAT-HSP27 and VEGF using microsphere/hydrogel hybrid systems for therapeutic angiogenesis.J Control Release. 2013 Feb 28;166(1):38-45. doi: 10.1016/j.jconrel.2012.12.020. Epub 2012 Dec 20. J Control Release. 2013. PMID: 23262200
-
A phosphodiesterase-5 inhibitor vardenafil enhances angiogenesis through a protein kinase G-dependent hypoxia-inducible factor-1/vascular endothelial growth factor pathway.Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1315-24. doi: 10.1161/ATVBAHA.109.201327. Epub 2010 Apr 22. Arterioscler Thromb Vasc Biol. 2010. PMID: 20413734
-
An update on angiogenesis therapy.Crit Rev Eukaryot Gene Expr. 2001;11(1-3):1-21. Crit Rev Eukaryot Gene Expr. 2001. PMID: 11693956 Review.
-
Role of the vascular endothelial growth factor isoforms in retinal angiogenesis and DiGeorge syndrome.Verh K Acad Geneeskd Belg. 2005;67(4):229-76. Verh K Acad Geneeskd Belg. 2005. PMID: 16334858 Review.
Cited by
-
Biomaterial delivery of morphogens to mimic the natural healing cascade in bone.Adv Drug Deliv Rev. 2012 Sep;64(12):1257-76. doi: 10.1016/j.addr.2012.05.006. Epub 2012 May 22. Adv Drug Deliv Rev. 2012. PMID: 22626978 Free PMC article. Review.
-
Guided bone regeneration using injectable vascular endothelial growth factor delivery gel.J Periodontol. 2013 Feb;84(2):230-8. doi: 10.1902/jop.2012.110684. Epub 2012 Jun 5. J Periodontol. 2013. PMID: 22668339 Free PMC article.
-
Peptide-Modified Nano-Bioactive Glass for Targeted Immobilization of Native VEGF.ACS Appl Mater Interfaces. 2022 Feb 2;14(4):4959-4968. doi: 10.1021/acsami.1c21378. Epub 2022 Jan 18. ACS Appl Mater Interfaces. 2022. PMID: 35041377 Free PMC article.
-
A two-compartment model of VEGF distribution in the mouse.PLoS One. 2011;6(11):e27514. doi: 10.1371/journal.pone.0027514. Epub 2011 Nov 8. PLoS One. 2011. PMID: 22087332 Free PMC article.
-
Experimental study of epidermal growth factor and acidic fibroblast growth factor in the treatment of diabetic foot wounds.Exp Ther Med. 2018 Jun;15(6):5365-5370. doi: 10.3892/etm.2018.6131. Epub 2018 May 3. Exp Ther Med. 2018. PMID: 29904416 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources